Biotech & therapeutics · Acute lung injury
GEn1E Lifesciences
A Palo Alto company built on a different way to hit p38 alpha kinase, a target big pharma abandoned twenty years ago. Its lead molecule has been in a Phase 2 ARDS trial since April 2023, and what that trial measures is safety.
A week in the ICU
Ritu Lal had filed more than 15 investigational new drug applications and carried three compounds to approval. Three, in 23 years. She found that hard to live with, even knowing the base rate.
“It kind of sucks, but it’s the industry standard that one out of 10 drugs makes it to FDA approval,” she told Fierce Biotech in 2019.
So she went looking for a disease where the arithmetic was worse and the science was further along than anyone realized. She landed on acute respiratory distress syndrome, in which the lining of the lung’s blood vessels stops holding and fluid floods the air spaces. Then she went and watched it happen.
“Approximately 200,000 patients in the U.S. have this disease and 40% of them die, which is devastating. There is no FDA-approved treatment, literally nothing. I spent a week in the ICU shadowing a pulmonologist and saw firsthand that there’s nothing to help them,” she said.
GEn1E, pronounced like genie, came out of Y Combinator’s Summer 2019 batch that August with, in Fierce Biotech’s words, “a little more than $1 million in seed funding.”
The target the industry walked away from
p38 alpha kinase sits near the top of the inflammatory cascade. In the late 1990s and early 2000s almost every large drugmaker built molecules to jam its catalytic site. Lal worked on them at Roche. The field crashed.
“At that point, none of us succeeded either because of safety issues or loss of efficacy,” she said.
The University of Maryland, Baltimore group that eventually supplied GEn1E’s chemistry argued that switching the enzyme off was the wrong idea to begin with, because p38 alpha does useful anti-inflammatory work too. Paul Shapiro in the School of Pharmacy and Jeffrey Hasday in the School of Medicine, with Alexander MacKerell’s computer-aided drug design center and Steven Fletcher, aimed at a pocket near the substrate binding groove instead. The enzyme keeps its catalytic activity. What it loses is its grip on MK2, the branch that drives cytokine output and endothelial leak. Lal had earned her PhD at that same school more than 20 years earlier.
“It was almost serendipity: We came across the p38alpha-specific, substrate-selective compound at the University of Maryland,” she said.
In December 2019 GEn1E took an exclusive, worldwide, all fields license to the p38 alpha program. In July 2022 it took a second UMB license on the same terms, covering ERK1 and ERK2 compounds.
Who runs it
Lal is founder, CEO and a board director. Co-founder Soujanya Bhumkar is a chemical engineer with an MBA from the University of Chicago who had already co-founded four technology startups. Fierce Biotech’s 2019 profile named a third figure, chief operating officer Clint Webb, as a co-founder; the team page captured in September 2026 does not list him. The board itself is visible only through SEC filings: the December 2022 Form D lists Lal, Bhumkar, Alan Levy and Noor Kamruddin, a partner at Clear Ventures, and the December 2025 filing adds François Nader, whom the company calls chairman.
License to clinic, measured in dates
First in human dosing began on January 7, 2021 at a single site in Christchurch, New Zealand, and finished on June 18, 2021 with 48 healthy volunteers. The Phase 2 study, NCT05795465, started on April 4, 2023: GEn-1124 given intravenously as soon as possible after ARDS diagnosis, a second dose about eight hours later, then twice daily for five days, in an estimated 52 patients. Primary completion is estimated for October 2026, and the study is still listed as recruiting.
BARDA backed an ARDS endotyping program in October 2023. The mechanism paper landed in October 2024. An oral formulation went through a six person pharmacokinetic study in November 2025. Then, on June 9, 2026, the FDA granted orphan drug and rare pediatric disease designations to a second compound, GEn-1123, for Duchenne muscular dystrophy. Seven years earlier, when GEn1E had no data of its own, Lal had named Duchenne as one of the diseases the chemistry might reach.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Phase 2 in ARDS | NCT05795465. Sponsor GEn1E, no collaborators. Start Apr 4, 2023, estimated enrollment 52, primary outcome safety and tolerability, primary completion estimated Oct 2026, status recruiting. A CenterWatch listing dated Jun 18, 2026 shows 11 centers, five active and recruiting, one completed, five not available. | Public record |
| First in human | NCT04728061. Phase 1a/1b, randomized, double blind, placebo controlled ascending intravenous doses, Christchurch, Jan 7 to Jun 18, 2021. Actual enrollment 48, against 64 in the registered summary. Primary outcome: incidence of adverse events. | Public record |
| Oral formulation | NCT07185113. Phase 1, single dose, open label, six healthy adult males, collaborator InClin, Oct 29 to Nov 4, 2025. Outcomes are plasma levels and safety measures. | Public record |
| Peer reviewed mechanism | One PubMed paper, J Pharmacol Exp Ther, Nov 22, 2024. In mice GEn-1124 “improved survival from 10%-40% in murine acute lung injury” and “from 0% to 50% in a mouse influenza pneumonia model”. | Public record |
| How that was announced | The October 2024 release describes the same experiments as “improving survival rates by 4-fold in acute lung injury and 5-fold in influenza-induced pneumonia”. The first figure matches. The second describes a rise from zero survival, which has no multiple. | Differs from the paper |
| Human efficacy | None reported. The company site groups proteomic panels under a heading of efficacy, but those samples come from the Phase 1 study, which enrolled healthy volunteers and measured pharmacokinetics, pharmacodynamics and safety. | Claim outruns the study |
| Discovery to Phase 2 in about 2.5 years | Stated on the company site and in the June 2026 release. The record: incorporated 2018, UMB license Dec 3, 2019, first in human Jan 7, 2021, Phase 2 start Apr 4, 2023. That is three years and four months after the license. | Differs from the record |
| Regulatory status | Orphan drug and rare pediatric disease designations for GEn-1123, Jun 9, 2026, covered by trade press. No registered GEn-1123 trial appears in the records pulled here. Fast Track for GEn-1124 is company-stated. | Independent |
| Assets and grants | Two exclusive UMB licenses, Dec 2019 and Jul 2022. BioWorld Science reported new GEn1E ERK patent filings in May 2025. No NIH or NSF awards appear in the grant records pulled here. | Independent |
Read plainly: the chemistry has a published mechanism and a first in human safety study behind it, and the regulatory paperwork is moving. What does not exist yet is a single clinical result in a patient. The Phase 2 now running was registered to measure safety, and it has been recruiting for three and a half years toward 52 subjects.
What to watch
- Primary completion of NCT05795465, estimated for October 2026, and whether that estimate moves again.
- Whether anything beyond safety is reported from a study whose registered primary outcome is adverse events.
- A registered trial for GEn-1123. Two FDA designations arrived without one on the public record.
- Peer reviewed publication of the human Phase 1 data. Only the mouse paper is in PubMed.
In their words
“Approximately 200,000 patients in the U.S. have this disease and 40% of them die, which is devastating. There is no FDA-approved treatment, literally nothing.”
Ritu Lal, founder and CEO, Fierce Biotech, 2019 · Interview
“This is all based on the literature because we haven’t generated our own data yet, but p38alpha kinase inhibitors work for muscle stem cell regeneration and they work for hearing loss, which I think is great. They also work for other diseases like Werner syndrome, Duchenne muscular dystrophy and Alzheimer’s.”
Ritu Lal, Fierce Biotech, 2019 · Interview
“We do not inhibit the anti-inflammatory pathways. It is very different from, say, a steroid or those drugs that are immunosuppressive.”
Ritu Lal, to Technical.ly, 2022 · Interview
“We have reasoned that the past clinical failure of previous generation p38 catalytic inhibitors reflects an intrinsic flaw in the strategy of inhibiting kinase activity.”
Paul Shapiro, PhD, inventor, University of Maryland School of Pharmacy, October 2024 release · Company release
“GEn-1124 offers a targeted way to destabilize the p38:MK2 complex without blocking p38 catalytic activity or ablating downstream signaling.”
Jeffrey Hasday, MD, University of Maryland School of Medicine, October 2024 release · Company release
“This designation really speaks to the massively unmet need, and GEn1E’s strong data.”
Ritu Lal on Fast Track status, Endurance28, an investor, May 2024 · Investor publication
“We believe GEn-1123 has the potential to become an oral small-molecule differentiated therapy that addresses key drivers of disease progression in patients who remain underserved by current treatment options.”
Ritu Lal, June 2026 designation release · Company release
Related companies
Sources
- Public recordClinicalTrials.gov NCT05795465, NCT04728061 and NCT07185113
- Public recordFirst-in-class MAPK p38 alpha to MK2 dual signal modulator
- Public recordForm D filings, GEn1E Lifesciences Inc., CIK 0001752886
- IndependentMeet GEn1E, the biotech bringing p38alpha kinase drugs to inflammatory diseases
- IndependentUMB licenses technology to Y Combinator-backed biotech startup
- IndependentUMB, in partnership with alumni, wants to commercialize rare disease treatments
- IndependentGEn-1123 wins orphan drug, rare pediatric disease status for DMD
- IndependentTrial listing for NCT05795465 with per site recruitment status
- IndependentGen1e Lifesciences presents new ERK inhibitors
- CompanyExclusive license for a University of Maryland, Baltimore compound
- CompanyPartnership with BARDA on the ASPECT endotyping program
- CompanyGEn1E publishes research on dual signal modulators
- CompanyFDA grants orphan drug and rare pediatric disease designations
- CompanyRiding the Fast Track to Pharma Success, an investor profile
- CompanyGEn1E Lifesciences website and Y Combinator company page
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
